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Abstract
Background: The risk for type 1 diabetes mellitus
(T1DM) and celiac disease (CD) is related to human
leukocyte antigen (HLA) DQA1, DQB1 and DRB1
loci. Unfortunately, HLA typing has been too difficult
and costly for frequent use. Automated genotyping
focused on risk alleles could provide access to HLA
typing in diagnostic evaluations, epidemiological
screening and contribute to preventive strategies.
Methods: A sequence specific primer amplification
method requiring a total of four PCR reactions, one
restriction enzyme digestion and a single electropho-
retic step provides low to medium resolution typing
of DQA1, DQB1 and DRB1 using Applied Biosystems
3730 DNA analyzer. The method was validated using
261 samples with genotypes determined using a
reference method.
Results: Specific fluorescent DQA1, DQB1 and DRB1
amplicons were of expected size. Concordance with
the reference method was 100% for DQA1 and DQB1
alleles and 99.8% for DRB1 alleles.
Conclusions: We have developed a high throughput
HLA typing method that accurately distinguishes risk
alleles for T1DM and CD. This method allows screen-
ing of several thousand samples per week, consum-
ing 32 ng of DNA template, low reagent volumes and
minimal time for data review.
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Introduction
The prevalence of type 1 diabetes mellitus (T1DM,
OMIM %222100) is 0.05%–0.4% in the general popu-
lation of Europe and the US (1–3), while the preva-
lence of celiac disease (CD, OMIM 212750) is close
to 1% and possibly higher in Northern European
countries (3–5). Both diseases occur during early
childhood, cluster in families, and significantly affect
health and family life-styles. Thus, risk assessment for
siblings and other family members is frequently
requested. Inter-action of environmental exposure
with a genetic predisposition for autoimmune disease
is well documented (6–10). The most important genes
contributing to disease susceptibility are located in
the human leukocyte antigen (HLA) class II region on
chromosome 6p21.3. For both diseases, a very limited
number of HLA DQA1 and DQB1 alleles appear to be
prerequisite for an immune reaction.
Numerous studies have demonstrated that DQB1*02
or *0302 expressed with DQA1*05 or DQA1*03,
respectively, confer a genetic risk for CD (11, 12).
About 90%–95% of patients with CD carry the
DQB1*02 allele together with DQA1*05 (encoded
either in cis or trans), compared to a prevalence of
20%–30% in the general population (13). Most of the
remaining 5%–10% have a DQ haplotype comprised
of DQA1*03 and DQB1*0302 (11, 14, 15), and nearly
no patients with CD lack both of these DQ risk
combinations. Studies have shown an increased risk
in individuals homozygous for DQB1*02 (15–17) and
an HLA-DQ risk gradient has been established for CD
(Table 1) (18). Thus, screening for DQB1*02 and *0302
allows very sensitive, but not specific, identification
of subjects at risk (19).
The situation is somewhat more complex, but
similar for T1DM, with risk also associated with
DQB1*0201 and *0302 alleles (20–22). However, this
risk appears to be modified by the accompanying
DRB1 alleles (21, 23–26). A continuous gradient from
highly predisposing to very protective haplotypes has
been demonstrated in various studies (24, 27, 28).
DRB1*04-DQB1*0302 or DRB1*03-DQB1*0201 are
present in 90%–95% of patients who develop T1DM
compared to 40%–45% of normal controls. Com-
pound heterozygotes carrying both of these haplo-
types confer an increased risk compared to
homozygotes for either haplotype. DRB1*15-
DQB1*0602, found in -1% of patients with T1DM and
20% of the general population, has a protective asso-
ciation with the disease (1, 29). Table 2 shows the HLA
risk association with T1DM.
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Table 1 CD risk associated with DQ combinations. Data from Megiorni et al. (18).
Haplotype 1 Haplotype 2 Risk
DQA1 DQB1 DQA1 DQB1
0501 0201 0301 0302 1:7
0501 0201 xa 0201b 1:10
0301 0302 xa 0201b 1:24
xa 0201b xa 0201b 1:26
0501 0201 0201b neg 1:35
0201 0202 0501 0301 1:35
0301 0302 0201b neg 1:89
xa 0201b 0201b neg 1:210
0501 0201 neg 0201b neg 1:1842
Other combinations 1:2518
ax differs from DQA1 *0501; b*02 is either DQB1*0201 or *0202.
In both CD and T1DM, the presence of a known risk
allele indicates significantly increased relative risk,
still lacking specificity. However, absence of all known
risk alleles has a high negative predictive value –
thus, obviating the need for additional diagnostic
testing.
Testing for HLA risk can be performed using com-
mercial kits such as Olerup SSP DQ (Genovision/
Qiagen, Oslo, Norway), Delfia HLA hybridization
assay (Perkin Elmer Life and Analytic Sciences Wal-
lac, Turku, Finland) or Dynal RELI SSO HLA typing
kit (Dynal Biotech Ltd, Bromborough, UK). These
methods require many reactions and/or multiple
steps. We present a novel automated high-throughput
PCR-SSP (sequence specific priming) method for
HLA-DRB1, DQA1 and DQB1 genotyping, optimized
for capillary electrophoresis using Applied Biosys-
tems 3730 or 3130xl DNA Analyzers (Applied Biosys-
tems, Foster City, CA, USA), with a specific focus on
risk alleles for T1DM and CD.
Materials and methods
DNA samples
DNA samples derived from affected sib-pair families or trios
were obtained following informed consent from participants
from five continents enrolled in the type 1 Diabetes Genetic
Consortium (T1DGC) (30). The project was approved by Eth-
ical Review Boards in each participating country. A sample
panel of 261 residual recoded DNA samples and 12 non-
template controls (NTC) used for proficiency testing within
the T1DGC HLA genotyping network were available with per-
mission for use to validate this method. The samples have
been genotyped by three accredited laboratories using a
proprietary high-resolution PCR-based sequence specific oli-
gonucleotide probe linear array (Roche Molecular Systems,
Pleasanton, CA, USA). There was 100% interlaboratory con-
sensus at these three loci, described by Mychaleckyj et al.
(manuscript submitted).
HLA-DQA1, DQB1 and DRB1 typing
DNA sequences of the second exon of HLA class II genes
were obtained from the IMGT/HLA database (31). Intronic
sequences were obtained from genebank sequences listed
in Bergström et al. (32) and Kotsch et al. (33). Sequence spe-
cific primers corresponding to exon 2 of the DQA1 and DQB1
genes, and to intron 1, exon 2 and intron 2 of the DRB1 gene,
were designed using Oligo 6.69 software (Molecular Biology
Insights Inc, Cascade, CO, USA). Four different primer mixes
were used, each containing at least one locus specific com-
mon primer labeled with a fluorescent dye specific for the
locus (NED, a yellow fluorescent color, for DQA1, VIC, a
green fluorescent color, for DQB1 and FAM, a blue fluores-
cent color, for DRB1) and several allele specific primers. The
common DRB1 primer was placed 39 to numerous micro-
satellite repeats to provide distinct class-specific amplicon
sizes. Special care was taken to prevent co-amplification of
the other existing DRB genes. All primers and primer mixes
are listed in Table 3.
All primers were diluted to a concentration of 2.5 mM.
Each PCR reaction contained 2 mL 4 ng/mL DNA, 0.6 mL
2.5 mM dNTP’s (GE Healthcare Bio-Sciences AB, Uppsala,
Sweden), 0.6 mL GeneAmp 10X PCR Buffer (500 mM KCl
and 100 mM Tris-HCl, pH 8.3), 0.6 mL 25 mM MgCl2, 0.05 mL
AmpliTaq Gold DNA Polymerase (5 U/mL) (Applied Biosys-
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Table 3 Primers and primer mixes used.
HLA primer mix Primer name and Primer sequence (59–39) Tm, Fragment Volume,
specificity 8Ca length, bpb mL
DQA1/DQB1 *05/*06 DQA1 all U *NED NEDGCCTCTTCAGGTGTAAACTTGTACCAGTc 73.2 – 0.40
DQA1*01 L GCCATGTTTCTCAGTGCACC 70.2 176 0.24
DQA1*02 L ATTGCGGGTCAAATCTAAGTCTGTG 72.9 154 0.10
DQA1*03 L CAAATCTCCTAAATCTGCGGAACAG 70.7 148 0.22
DQA1*04/*05/*06 L CTAAATTGTCTGAGAACAGGCAAACA 71.1 140 0.28
DQA1*05 L CGCAGACTGTTCAAGTTATGTTTTAGG 71.6 203 0.16
DQB1*05/*06 L *VIC VICCGACGACGCTCACCTCTCCTd 73.8 – 0.40
DQB1*05 U GTGCGGGGTGTGACCAGAC 73.7 227 0.15
DQB1*06 U GGAGCGCGTGCGTCTTGTAA 75.3 234 0.30
DQB1*0601 U GACGGAGCGCGTGCGTTA 75.4 236 0.15
DQB1 *02/*03/*04 DQB1*02/*03/*04 L *VIC VICGTCGTGCGGAGCTCCAACT 72.4 – 0.80
DQB1*02 U CGTGCGTCTTGTGAGCAGAA 72.2 201 0.32
DQB1*04 U GCGGGGTGTGACCAGATACA 72.8 198 0.16
DQB1*0301/*0303 U GCTGGGGCCGCCTGA 74.6 114 0.28
DQB1*0301/*0304 U GACAGCGACGTGGAGGTGTAC 71.5 149 0.10
DQB1*0302/*0303 U GAGCGCATGCGTCTTGTGACe 74.0 206 0.36
DRB1 mix I DRB1 all L *FAM FAMCTAAATGCTCACAGATGGCGCTCTCTCTC 78.9 – 0.80
DRB1*01 U CGTTTCTTGTGGCAGCTTAAGTT 70.3 f 0.40
DRB1*04 U CGGAGGCCGCTTCTGTA 69.6 f 0.40
DRB1 mix II DRB1 all L *FAM FAMCTAAATGCTCACAGATGGCGCTCTCTCTC 78.9 – 0.65
DRB1*03/*11/*13/*14 U CACGTTTCTTGGAGTACTCTACGTC 68.9 f 0.40
DRB1*07 U CACGTTTCCTGTGGCAGGG 73.5 f 0.40
DRB1*08/*12 U CACGTTTCTTGGAGTACTCTACGGG 72.6 f 0.30
DRB1*09 U CGGTATCTGCACAGAGGCAT 69.7 f 0.30
DRB1*10 U GGTTGCTGGAAAGACGCGTCC 76.8 f 0.30
DRB1*15/*16 U CGTTTCCTGTGGCAGCCTAAGAG 74.7 f 0.30
aThe melting temperature (Tm) of the primer; bthe calculated fragment length in basepairs (bp); cCA, mismatch against all
DQA1 alleles; dCGACGACGCTCA, intron sequence; eA, mismatch; fsee supplemental data Table 1.
tems), 2 mL primer mix (Table 3), and H2O to a final volume
of 6 mL.
PCR reactions were performed in barcoded 96- or 384-well
plates (Abgene, Epsom, UK) using a GeneAmp PCR system
9700 (Applied Biosystems). The DQB1 *02/*03/*04, DRB1
mix I and DRB1 mix II were amplified following initial dena-
turation at 958C for 10 min, with 45 cycles at 948C for 1 min,
668C for 30 s and 728C for 1 min, and a final 10 min at 728C.
DQA1/DQB1 *05/*06 was amplified using the same condi-
tions, with the exception of a 648C annealing temperature.
Following amplification, 7.5 mL of a digestion mixture con-
taining 1.25 mL Buffer Bq (10 mM Tris-HCl, pH 7.5; 10 mM
MgCl2, 0.1 mg/mL BSA), 0.1 mL of the restriction endonu-
clease Cfr42I (10 U/mL) (Fermentas Sweden, Helsingborg,
Sweden) and 6.15 mL H2O was added to each 6 mL of DRB1
mix I PCR reaction and incubated at 378C for 2 h. This
enzyme cleaves DRB1*04 subtypes associated with T1DM
risk, i.e., *0401, *0402, *0404, *0405 and *0408, leaving the
protective or neutral subtypes such as, *0403, *0406 and
*0407 undigested.
The DQA1/DQB1 *05/*06 and DQB1 *02/*03/*04 PCR reac-
tions were diluted 1:10 in water. Eight mL of 2% GeneScan
500 LIZ standard in HiDi Formamide (Applied Biosystems)
was dispensed into each well in a barcoded MicroAmp plate
(Applied Biosystems). Next, 1 mL of each PCR reaction, i.e.,
diluted DQA1/DQB1 *05/*06 and DQB1 *02/*03/*04, DRB1
mix II and the digested DRB1 mix I was added to each well.
All mixing and dispensing steps were performed using a
Multimek 96 robot (Beckman Coulter, Fullerton, CA, USA).
The PCR products were denatured by a single heating step
at 958C for 5 min prior to electrophoresis using a 36-cm cap-
illary with a 3730 DNA Analyzer and Fragment Analysis Run
Module, POP-7 polymer and the G5 dye set. Analysis time
for a 96 well plate is ;1 h. Some analyses were also per-
formed using a 3130xl Genetic Analyzer, requiring 3 h per
run.
Detected fragment sizes were correlated to the LIZ-labeled
internal standard peaks on the x-axis. Each HLA locus is
represented by a specific fluorescent dye and each analyzed
allele is represented by a specific size. Automated allele call-
ing was performed using GeneMapper v 3.0 (Applied Bio-
systems). All allele calls were verified by manual inspection
of the GeneMapper images and haplotype checks were per-
formed before final allele designation.
Results
The NED-labeled DQA1 specific amplicons, VIC-
labeled DQB1 specific amplicons and FAM-labeled
DRB1 specific amplicons were easily distinguished by
GeneMapper. Figure 1 shows the electropherograms
produced by a sample with the genotype DRB1*0401/
*0301, DQA1*03/*05, DQB1*02/*0301. True peaks
could be distinguished readily from background noise
by amplitude and position. Concordance with the ref-
erence method was 100% (522/522) for DQA1 alleles,
100% (522/522) for DQB1 alleles, and 99.8% (521/522)
for DRB1 alleles at the resolution level indicated in
Supplemental data Table 2. No signal was seen for
any NTC.
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Figure 1 Electropherograms produced by a sample with the genotype DRB1*0401/*0301, DQA1*03/*05, DQB1*02/*0301.
The position of each peak on the x-axis corresponds to the size of a PCR fragment. Peak heights correspond to the amount of
detected PCR product. al, allele; sz, size; ht, height.
DQ allelic assignments
The sizes of all allele specific amplicons agreed with
those expected and no overlap occurred, as shown in
Supplemental data Figure 1. Although DQA1*06 can-
not be distinguished from DQA1*04, and heterozy-
gous DQA1*04/*05 and *05/*06 samples cannot be
distinguished from homozygous DQA1*05/*05, such
ambiguities can be resolved by haplotype analysis
together with DRB1 and DQB1 data, choosing the
most preferential allele identification as DR and DQ
alleles exist in common although not entirely consis-
tent linkage. Similarly, some heterozygous combina-
tions of DQB1*03 alleles appear ambiguous, but can
be distinguished using haplotype association.
DRB1 allelic assignments
Whereas most DRB1 alleles produced expected
amplicon lengths, some displayed size variation due
to a variable microsatellite in intron 2. Thus, a range
of fragment sizes occurred with evident overlap
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between some allelic groups, see Supplemental data
Figure 2. This method was able to distinguish the
T1DM susceptible DRB1*04 subtypes *0401, *0402,
*0404 and *0405 from the neutral or protective sub-
types DRB1 *0403 and *0407. Of the 191 alleles typed
as DRB1*04 susceptible, one sample was DRB1*0419,
which is very uncommon and the disease association
is not known. DRB1*0403, *0407, *07, *09 and *10
alleles produced fragments of distinctive lengths.
DRB1*03, *08, and *16 alleles could be easily identi-
fied by referring to DR-DQ haplotypes. The DRB1*11,
*12, *13, *14 and *15 alleles, which are generally
neutral, were designated DRB1*X as some overlap
occurred. The T1DM protective DRB1*1401 and *1501
alleles could be differentiated from the DRB1*X group
by size and haplotype association in 95% (82/86) of
the cases. All analyzed haplotypes and the corre-
sponding results, presumed by known linkage dis-
equilibrium, are shown in Supplemental data Table 2.
Discussion
The major clinical importance of the HLA DR-DQ
region is well established for CD and T1DM, and other
associations within the HLA region are being investi-
gated for rheumatoid arthritis, Morbus Addison and
other diseases. Due to the extreme variability seen in
this region, very large study populations are required
to attain statistical power of association with other
specific diseases.
To meet current local demands for an HLA method
for the study of T1DM and CD, we developed a high
throughput SSP genotyping method. Our method
requires a maximum of 32 ng DNA templates, four
PCR reactions, one restriction enzyme digestion and
a single electrophoretic step using an automated DNA
analyzer and automated allele assignment.
As specific risk alleles for these diseases are well
established, high resolution of all neutral alleles is
unnecessary. If a focus on other alleles is necessary,
the method can be modified by exchange or addition
of new primers and validation.
Since concordance of the DQA1 and DQB1 typing
was 100%, and all DQ alleles associated with CD, i.e.,
DQA1*05-DQB1*02 and DQA1*03-DQB1*0302 could
be distinguished from other alleles, this method is
sufficiently sensitive and specific for clinical use to
confirm or exclude the possibility of CD. Additionally,
DQB1 *02 homozygosity could be determined in the
absence of another DQB1 allele since at least one pri-
mer for every DQB1 allele group (i.e., *02, *03, *04,
*05, *06) was included in the analysis.
The positive predictive value of the presence of
these risk alleles is low. Thirty to forty percent of the
Caucasian population carries at least one of these DQ
combinations, and only 1%–4% of these individuals
have CD (10). In contrast, the negative predictive val-
ue of their absence is )99.5% (12). Therefore, HLA
genotyping can be useful for precluding the necessity
for further invasive diagnostic testing or to exclude
risk in relatives. It is estimated that most cases of CD
remain undiagnosed, and untreated CD can cause
long-term health problems. Thus, targeted screening
in families of CD probands could identify such undiag-
nosed individuals and prevent lifelong symptoms and
complications (4).
As for CD, the DQB1*02 and/or *0302 alleles are
present in nearly all T1DM cases. By including the
restriction enzyme digestion step of DRB1*04 and *01
PCR products, DRB1*01 could be differentiated from
other DRB1 alleles and DRB1 subtypes *0401, *0402,
*0404, *0405 associated with T1DM disease risk could
be differentiated from *0403 and *0407 which are
considered protective, even when present on the
same ‘‘high-risk’’ DQA1*03-DQB1*0302 haplotype
(24). Also, the less common DRB1*08-DQA1*
04-DQB1*04 and DRB1*01-DQA1*01-DQB1*05 risk
alleles could be easily distinguished by this assay.
Although allele frequencies and relative risks vary sig-
nificantly in different populations and publications
(24, 27, 28), essentially no cases lacking the above
named alleles are seen in T1DGC cases (data
unpublished).
A high-throughput screening assay such as that
presented here could be useful in population studies
such as ongoing prospective neonatal screening pro-
grams assessing T1DM risk (9, 34, 35). Also, analysis
of HLA-DR-DQ alleles may be important for discrimi-
nating between subjects at high or intermediate risk
from antibody positive individuals carrying protective
haplotypes (36).
In our validation study using 261 samples from fam-
ilies with T1DM from five continents, DRB1 typing
made one incorrect identification only. Even though
the sample panel originates from a T1DM study, 28 of
the most common Caucasian haplotypes are repre-
sented in the dataset, covering all haplotypes with a
frequency )0.3% in the general Caucasian popula-
tion. In addition, several rare haplotypes are included
in the dataset. However, we would caution that the
efficiency of some markers in the screening protocol
may depend on the population being studied, as allele
frequencies and microsatellite repeats vary among
different populations. It is therefore wise to validate
this method against samples with known genotypes
in different settings.
We developed an economical, high throughput HLA
typing method that accurately distinguishes risk
alleles for T1DM and CD with a degree of accuracy of
100% for DQA1, 100% for DQB1 and 99.8% for DRB1
genotyping. Simultaneous detection of DRB1, DQA1
and DQB1 alleles allows resolution of many potential
ambiguities by reference to common haplotype asso-
ciations. Although the method is not intended for
matching of donors and recipients in the context of
transplantation, it provides equal or better resolution
compared with many available commercial kits and is
well suited for clinical screening (e.g., as a negative
predictor for CD or T1DM). The multiplex concept of
this basic PCR-SSP capillary electrophoresis method
is amenable to adaptation for many different disease
associations.
By using locus specific fluorescent markers and
capillary electrophoresis, multiple PCR products from
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all three loci can be automatically resolved by size,
analyzed and typed in a single step. With a total
requirement of 32 ng DNA template, HLA typing
becomes possible using dried blood spots for DNA
template. The low reagent costs and rapid interpre-
tation allows analysis of high-risk alleles in epidemi-
ological as well as clinical settings.
Supplementary data associated with this article can be found
in the online version at: http://www.reference-global.com/
doi/suppl/10.1515/CCLM.2009.346.
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